Daratumumab depletes CD38(+) immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Daratumumab targets CD38-expressing myeloma cells through a variety of immune-mediated mechanisms (complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis) and direct apoptosis with crosslinking. These mechanisms may also target...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Blood
मुख्य लेखकों: Krejcik, Jakub, Casneuf, Tineke, Nijhof, Inger S., Verbist, Bie, Bald, Jaime, Plesner, Torben, Syed, Khaja, Liu, Kevin, van de Donk, Niels W. C. J., Weiss, Brendan M., Ahmadi, Tahamtan, Lokhorst, Henk M., Mutis, Tuna, Sasser, A. Kate
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Hematology 2016
विषय:
Immunobiology
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4957162/
https://ncbi.nlm.nih.gov/pubmed/27222480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-12-687749
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन